Targeted lipid nanoparticles for antisense oligonucleotide delivery

Current Pharmaceutical Biotechnology

Volumn 15, Issue 9, 2014, Pages 847-855

  Petrilli, Raquel ^a,b   Eloy, Josimar O ^a,b   Marchetti, Juliana M ^a   Lopez, Renata F V ^a   Lee, Robert J ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotides; Liposomes; Nanoparticles; Targeting

Indexed keywords

ALEMTUZUMAB; ANTISENSE OLIGONUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; CD19 ANTIBODY; CD2 ANTIGEN; CD20 ANTIBODY; CD32 ANTIGEN; CD4 ANTIBODY; CD40 ANTIGEN; CELL PENETRATING PEPTIDE; CELL SURFACE RECEPTOR; CETUXIMAB; CYCLOHEXYL(PHENYL)(2 PIPERIDINOETHYL)SILANOL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; GAMMA INTERFERON; INTERLEUKIN 10; LIPID NANOPARTICLE; LIPOSOME; MESSENGER RNA; NANOCARRIER; NANOPARTICLE; OLIGOSACCHARIDE; POLYSACCHARIDE; RITUXIMAB; SINGLE STRANDED DNA; TRANSFERRIN; TRASTUZUMAB; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIBODY; FOLIC ACID; LIPID; PEPTIDE;

ANTISENSE THERAPY; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; BIOACCUMULATION; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL ENCAPSULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; ELECTROPORATION; GENE EXPRESSION REGULATION; GENE TARGETING; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MELANOMA; NEUROBLASTOMA; PROTEIN EXPRESSION; PROTEIN MOTIF; TOXICITY; ANIMAL; CHEMISTRY;

ANIMALS; ANTIBODIES; FOLIC ACID; HUMANS; LIPIDS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; POLYSACCHARIDES; TRANSFERRIN;

EID: 84920571100     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666141020155834     Document Type: Article

References (89)

1. [1] Stahel, R.A.; Zangemeister-Wittke, U. Antisense oligonucleotides for cancer therapy - an overview. Lung Cancer, 2003, 41, 581-588.
2. [2] Merdan, T.; Kopecek, J.; Kissel, T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug De-liv. Rev., 2002, 54, 715-758.
3. [3] Miller, K.J.; Das, S.K. Antisense oligonucleotides: strategies for delivery. Pharm. Sci. Technol. Today, 1998, 1(9), 377-386.
4. [4] Jansen, B.; Zangermeister-Wittke, U. Antisense therapy for cancer-the time of truth. Lancet Oncol., 2002, 3, 672-683.
5. [5] Xu, D.; Kang, H.; Fisher, M.; Juliano, R.L. Strategies for Inhibition of MDR1 Gene Expression. Mol. Pharmacol., 2004, 55(2), 268-275.
6. [6] Takabatake, Y.; Isaka, Y.; Mizui, M.; Kawachi, H.; Shimizu, F.; Ito, T.; Hori, M.; Imai, E. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther., 2005, 12(12), 965-73.
7. [7] Fattal, E.; Couveur, P.; Dubernet, C. “Smart” delivery of antisense oligonucleotides by anionic pH-sentive liposomes. Adv. Drug De-liv. Rev., 2004, 56, 931-946.
8. [8] Fattal, E.; Bochot, A. State of the art and perspectives for the deliv-ery of antisense oligonucleotides and siRNA by polymeric nanocar-riers. Int. J. Pharm., 2008, 364, 237-248.
9. [9] Visser, M.E.; Witztum, J.L.; Stroes, E.S.G.; Kastelein, J.J.P. An-tisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J., 2012, 33, 1451-1458.
10. [10] Deleavey, G.F.; Damha, M.J. Designing chemically modified oli-gonucleotides for targeted gene silencing. Chem. Biol., 2012, 19, 937-954.
11. [11] Myers, K.J.; Dean, N.M. Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol. Sci., 2000, 21, 19-23.
12. [12] Bochot, A.; Couvreur, P.; Fattal, E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res., 2000, 19(2), 131-147.
13. [13] Yu, B.; Zhao, X.; Lee, L.J.; Lee, R.J. Targeted delivery systems for oligonucleotide therapeutics. The AAPS Journal, 2009, 11(1), 195-203.
14. [14] Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev., 2012, 11, 125-140.
15. [15] Juliano, R.; Alam, Md. R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 2008, 36(12), 4158-4171.
16. [16] Felber, A.R.; Bayó-Puxan, N.; Deleavey, G.F.; Castagner, B.; Damha, M.J.; Leroux, J.C. The interactions of amphiphilic an-tisense oligonucleotides with serum proteins and their effects on in vitro silencing activity. Biomaterials, 2012, 33, 5955-5965.
17. [17] Hughes, M.D.; Hussain, M.; Nawaz, Q.; Sayyed, P.; Akhtar, S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today, 2001, 6(6), 303-315.
18. [18] Kawakami, S.; Higuchi, Y.; Hashida, M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J. Pharm. Sci., 2008, 97(2), 726-745.
19. [19] Lee, S.H.; Castagner, B.; Leroux, J.C. Is there a future for cell-penetrating peptides in oligonucleotide delivery?. Eur. J. Pharm. Biopharm., 2013, 85, 5-11.
20. [20] Aboul-Fald, T. Antisense oligonucleotides: the state of the art. Curr. Med. Chem., 2005, 12, 2193-2214.
21. [21] Rayburn, E.R.; Zhang, R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Dis-cov. Today, 2008, 13(11, 12), 513-521.
22. [22] Wang, S.; Zhang, X.; Yu, B.; Lee, R.J.; Lee, J. Targeted nanoparti-cles enhanced flow electroporation of antisense oligonucleotides in leukemia cells. Biosens. Bioelectron., 2010, 26(2), 778-783.
23. [23] Cuomo, F.; Mosca, M.; Murgia, S.; Ceglie, A.; Lopez, F. Oligonu-cleotides and polynucleotides condensation onto liposome surface: Effects of the base and of the nucleotide length. Colloids Surf. B., 2013, 104, 239-244.
24. [24] Sasaki, M.; Hayashi, J.; Fujii, M.; Koizumi, K.; Fujita, H.; Kobaya-shi, M.; Kawakubo, Y.; Ito, A. Neutral liposome-mediated delivery process of fluorescein-modified oligonucleotides in cultured human keratinocytes. J. Photochem. Photobiol. B-Biol., 2001, 60, 120-128.
25. [25] Zhong, J.; Yao, X.; Li, D.L.; Li, L.Q.; Zhou, L.F.; Huang, H.L.; Min, L.S.; Li, J.; Fu, F.F.; Dai, L.C. Large scale preparation of midkine antisense oligonucleotides nanoliposomes by a cross-flow injection technique combined with ultrafiltration and high-pressure extrusion procedures. Int. J. Pharm., 2013, 441, 712-720.
26. [26] Paszko, E.; Senge, M.O. Immunoliposomes. Curr. Med. Chem., 2012, 19, 5239-5277.
27. [27] Trabulo, S.; Resina, S.; Simões, S.; Lebleu, B.; Pedroso de Lima, M.C. A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J. Control. Release, 2010, 145(2), 149-158.
28. [28] Han, M.; Chen, J.L.; Hu, Y.; He, C.L.; Shuai, W.P.; Yu, J.H.; Chen, H.L.; Liang, W.Q.; Mayumi, T.; Shinsaku, N.; Gao, J.Q. In vitro and in vivo tumor suppressive activity induced by human te-lomerase transcriptase-targeting antisense oligonucleotides mediated by cationic liposomes. J. Biosci. Bioeng., 2008, 106(3), 243-247.
29. [29] Chaumont, G.; Seksek, O.; Grzybowska, J.; Borowski, E.; Bolard, J. Delivery systems for antisense oligonucleotides. Pharmacol Ther., 2000, 87(2-3), 255-77.
30. [30] Remaut, K.; Lucas, B.; Braeckmans, K.; Sanders, N.N.; Demeester, J.; De Smedt, S.C. Protection of oligonucleotides against nucleases by PEGylated and non-PEGylated liposomes as studied by fluorescence correlation spectroscopy. J. Control. Release, 2005, 110(1), 212-226.
31. [31] Pedroso de Lima, M.C.; Simões, S.; Pires, P.; Faneca, H.; Düz-günes, N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Deliv. Rev., 2001, 47(2, 3), 277-294.
32. [32] Chen, J.; Sun, X.; Gao, J.; Liang, W. Influence of lipid components on gene delivery by polycation liposomes: transfection efficiency, intracellular kinetics and in vivo tumor inhibition. Int. J. Pharm., 2012, 422(1, 2), 510-515.
33. [33] Zimmermann, T.S.; Lee, A.C.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M.N.; Harborth, J.; Heyes, J.A.; Jeffs, L.B.; John, M.; Judge, A.D.; Lam, K.; McClintock, K.; Nechev, L.; Palmer, L.R.; Racie, T.; Röhl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.; Soutschek, J.; Toudjarska, I.; Wheat, A.J.; Yaworski, E.; Zedalis, W.; Koteliansky, V.; Manoharan, M.; Hornlocher, H-P.; MacLach-lan, I. RNAi-mediated gene silencing in non-human primates. Nature, 2006, 441, 111-114
34. [34] Maeda, H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release, 2012, 164(2), 138-144.
35. [35] Allen, T.M.; Cullis, P.R. Liposomal drug delivery: from concept to clinical applications. Adv. Drug Deliv. Rev., 2013, 65(1), 36-48.
36. [36] Pakunlu, R.I.; Wang, Y.; Saad, M.; Khandare, J.J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release, 2006, 114(2), 153-162.
37. [37] Mui, B.L.; Tam, Y.K.; Jayaraman, M.; Ansell, S.M.; Du, X.; Tam, Y.Y.C.; Lin, P.J.C.; Chen, S.; Narayanannair, J.K.; Rajeev, K.G.; Manoharan, M.; Akinc, A.; Maier, M.A.; Cullis, P.; Madden, T.D.; Hope, M.J. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol. Ther. Nucleic Acids, 2013, 2, e139.
38. [38] De Oliveira, M.C.; Fattal, E.; Couvreur, P.; Lesieur, P.; Bourgaux, C.; Ollivon, M.; Dubertnet, C. pH sensitive liposomes as carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quase-anhydrous samples. Biochim. Biophys. Acta, 1998, 1372(2), 301-310.
39. [39] Jääskeläinen, I.; Stemberg, B.; Mönkkönen, J. Urtti, A. Physico-chemical and morphological properties of complexes made of cati-onic liposomes and oligonucleotides. Int. J. Pharm., 1998, 167(1, 2), 191-203.
40. [40] Goyal, P.; Goyal, K.; Kumar, S.G.V.; Sing, A.; Katare, O.P., Mishra, D.N. Liposomal drug delivery systems - Clinical applications. Acta Pharm., 2005, 55, 1-25.
41. [41] Noble, G.T.; Stefanick, J.F.; Ashley, J.D.; Kiziltepe, T.; Bilgicer, B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol., 2014, 32(1), 32-46.
42. [42] Ahmadvand, D.; Rahbarizadeh, D.; Moghimi, S.M. Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). Curr. Opin. Biotechnol., 2011, 22(6), 832-838.
43. [43] Christiansen, J.; Rajasekaran, A.K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther., 2004, 3, 1493-1501.
44. [44] Park, J.W.; Benz, C.C.; Martin, F.J. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin. Oncol., 2004, 31(13), 196-205.
45. [45] Brignole, C.; Marimpietri, D.; Pastorino, F.; Di Paolo, D.; Pagnan, G.; Loi, M.; Piccardi, F.; Cilli, M.; Tradori-Cappai, A.; Arrigoni, G.; Pistoia, V.; Ponzoni, M. Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides. J. Control. Rel., 2009, 138, 122-127.
46. [46] Yu, B.; Mao, Y.; Bai, L.Y.; Herman, S.W.M.; Wang, X.; Ra-manunni, A.; Jin, Y.; Mo, X.; Cheney, C.; Chan, K.K.; Jarjoura, D.; Marcucci, G.; Lee, R.J.; Byrd, J.C.; Lee, L.J.; Muthusamy, N. Targeted nanoparticle delivery overcomes off-target immunostimula-tory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood, 2013, 121, 136-147.
47. [47] Selvam, M.P.; Buck, S.M.; Blay, R.A.; Mayner, R.E.; Mied, P.A.; Epstein, J.S. Inhibition of HIV replication by immunoliposomal an-tisense Oligonucleotides. Antiviral Res., 1996, 33, 11-20.
48. [48] Pastorino, F.; Stuart, D.; Ponzoni, M.; Allen, T.M. Targeted delivery of antisense oligonucleotides in cancer. J. Control. Rel., 2001, 74, 69-75.
49. [49] Brignole, C.; Pagnan, G.; Marimpietri, D.; Cosimo, E.; Allen, T.M.; Ponzoni, M.; Pastorino, F. Targeted delivery system for an-tisense oligonucleotides: a novel experimental strategy for neuro-blastoma treatment. Cancer Lett., 2003, 197, 231-235.
50. [50] Pastorino, F.; Brignole, C.; Marimpietri, D.; Di Paolo, D.; Zan-colli, M.; Pagnan, G.; Ponzoni, M. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Ann. N.Y. Acad. Sci., 2004, 1028, 90-103.
51. [51] Brignole, C.; Marimpietri, D.; Pagnan, G.; Di Paolo, D.; Zancolli, M.; Pistoia, V.; Ponzoni, M.; Pastorino, F. Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities. Cancer Lett., 2005, 228, 181-186.
52. [52] Ma, D.D.F.; Wei, A-Q. Enhanced delivery of synthetic oligonu-cleotides to human leukaemic cells by liposomes and immu-noliposomes. Leukemia Res., 1996, 20, 925-930.
53. [53] Stuart, D.D.; Kao, G.Y.; Allen, T.A. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleo-tides targeted against MDR1. Cancer Gene Ther., 2000, 7(3), 466-475.
54. [54] Kwong, B.; Liu, H.; Irvine, D.J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials, 2011, 32, 5134-5147.
55. [55] Zelphati, O.; Zon, G.; Leserman, L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated inimmunoliposomes. Antisense Res. Dev., 1993, 3(4), 323-38.
56. [56] Zelphati, O.; Imbach, J-L.; Signoret, N.; Zon, G.; Rayner, B.; Le-serman, L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res., 1994, 22(20), 4307-4314.
57. [57] Liu, M.; Li, M.; Sun, S.; Li, B.; Du, D.; Sun, J.; Cao, F.; Li, H.; Jia, F.; Wang, T.; Chang, N.; Yu, H.; Wang, Q.; Peng, H. The use of antibody modified liposomes loaded with AMO-1 to deliver oli-gonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials, 2014, 35, 3697-3707.
58. [58] Torchilin, V.P. Tat peptide-mediated intracelular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev., 2008, 60, 548-558.
59. [59] Bechara, C.; Sandrine, S.; Cell-penetrating peptides: 20 years later, where do we stand?. FEBS Letters, 2013, 587, 1693-1702.
60. [60] Koren, E.; Torchilin, V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med., 2012, 18(7), 385-393.
61. [61] Saw, P.E.; Ko, Y.T.; Jon, S. Efficient liposomal nanocarrier-mediated oligodeoxynucleotide delivery involving dual use of a cell-penetrating peptide as a packaging and intracellular delivery agent. Macromol. Rapid Commun., 2010, 31, 1155-1162.
62. [62] Santos, A.O.; Da Silva, L.C.G.; Bimbo, L.M.; De Lima, M.C.P.; Simões, S.; Moreira, J.N. Design of peptide-targeted liposomes containing nucleic acids. Biochim. Biophys. Acta, 2010, 1798, 433-441.
63. [63] Geromel, V.; Cao, A.; Briane, D.; Vassy, J.; Rotig, A.; Rustin, P.; Coudert, R.; Rigaut, J.P.; Munnich, A.; Taillandier, E. Mitochondria transfection by oligonucleotides containing a signal peptide and vectorized by cationic liposomes. Antisense Nucleic Acid Drug Dev., 2001, 11, 175-180.
64. [64] Liu, X.Q.; Song, W.J.; Sun, T.M.; Zhang, P.Z.; Wang, J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm., 2011, 8(1), 250-259
65. [65] Kibria, G.; Hatakeyama, H.; Ohga, N.; Hida, K.; Harashima, H. Dual-ligand modification of PEGulated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release, 2011, 153, 141-148.
66. [66] Higuchi, Y.; Kawakami, S.; Yamashita, F.; Hashida, M. The potential role of fucosylated cationic liposome/NF-κB decoy complexes in the treatment of cytokine-related liver disease. Bio-materials, 2007, 28, 532-539.
67. [67] Wijagkanalan, W.; Kawakami, S.; Higuchi, Y.; Yamashita, F.; Hashida, M. Intratracheally instilled mannosylated cationic liposome/NF-κB decoy complexes for effective prevention of LPS-induced lung inflammation. J. Control. Release, 2011, 149, 42-50.
68. [68] Huang, H.; Sakurai, F.; Higuchi, Y.; Kawakami, S.; Hashida, M.; Kawabata, K.; Mizuguchi, H. Suppressive effects of sugar-modified cationic liposome/ NF-κB decoy complexes on adeno-vierus vector-induced innate immune responses. J. Control. Release, 2009, 133, 139-145.
69. [69] Dinh, T.D.; Higuchi, Y.; Kawakami, S.; Yamashita, F.; Hashida, M. Evaluation of osteoclastogenesis via NF-κB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cyto-kine production from primary cultured macrophages. Pharm. Res., 2011, 28, 742-751.
70. [70] Higuchi, Y.; Kawakami, S.; Oka, M.; Yabe, Y.; Yamashita, F.; Hashida, M. Intravenous administration of mannosylated cationic liposome/ NF-κB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Letters, 2006, 580, 3706-3714.
71. [71] Yu, F.; Jiang, T.; Zhang, J.; Cheng, L.; Wang, S. Galactosylated liposomes as oligodeoxynucleotides carrier for hepatocyte-selective targeting. Pharmazie, 2007, 62(7), 528-533.
72. [72] Wang, S.L.; Yu, F.B.; Jiang, T.Y.; Sun, C.S.; Wang, T.; Zhang, J.H. Design and synthesis novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialglycopro-tein receptor. J. Drug Target, 2008, 16(3), 233-242.
73. [73] Wen, S.Y.; Wang, X.H.; Guan, W.; Wang, S.Q. Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome. World J. Gastroenterol., 2004, 10(2), 244-249.
74. [74] Bandyopadhyay, P.; Kren, B.T.; Ma, X.; Steer, C.J. Enhanced gene transfer into HuH-7 cells and primary rat hepatocytes using targeted liposomes and polyethylenimine. Biotechniques., 1998, 25(2), 286-292.
75. [75] Bandyopadhyay, P.; Ma, X.; Linehan-Stieers, C.; Kren, B.T.; Steer, C.J. Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNa oligonucleotides. J. Biol. Chem., 1999, 274, 10163-10172.
76. [76] Wang, S.; Cheng, L.; Yu, F.; Pan, W.; Zhang, J. Delivery of different length poly(L-lysine)-conjugated ODN to HepG2 cells using N-stearyllactobionamide-modified liposomes and their enhanced cellular biological effects. Int. J. Pharm., 2006, 311, 82-88.
77. [77] Zhang, Y.; Qi, X.R.; Gao, Y.; Wei, L.; Maitani, Y.; Nagai, T. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J. Control. Release, 2007, 117, 281-290.
78. [78] Kanasty, R.; Dorkin, J.R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nature Mater., 2013, 12, 967-977.
79. [79] Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54(5), 675-693.
80. [80] Zhao, X.B.; Lee, R.J. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev., 2004, 56(8), 1193-1204.
81. [81] Low, P.S.; Henne, W.A; Doorneweerd, D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res., 2008, 41(1), 120-129.
82. [82] Sudimack, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 2000, 41(2), 147-162.
83. [83] Zhou, W.; Yuan, X.; Yang, L.; Mokotoff, M.; Pitt, B.; Li, S. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug. Chem., 2002, 13(6), 1220-1225.
84. [84] Yang, L.; Li, J.; Zhou, W.; Yuan, X.; Li, S. Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells. J. Control. Release, 2004, 95(2), 321-331.
85. [85] Leamon, C.P.; Cooper, S.R.; Hardee, G.E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem., 2003, 14(4), 738-747.
86. [86] Rait, A.S.; Pirollo, K.F.; Xiang, L.; Ulick, D.; Chang, E.H. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 leves. Mol. Med., 2002, 8(8), 475-486.
87. [87] Daniels, T.R.; Bernabeu, E.; Rodríguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta., 2012, 1820(3), 291-317.
88. [88] Chiu, S.J.; Liu, S.; Perrotti, D.; Marcucci, G.; Lee, R.J. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J. Control. Release, 2006, 112(2), 199-207.
89. [89] Mendonça, L.S.; Firmino, F.; Moreira, J.N.; Pedroso de Lima, M.C.; Simões, S. Tranferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconj. Chem., 2010, 21(1), 157-168.